Literature DB >> 18708076

Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain.

Mostafa El Mansari1, Ramez Ghanbari, Shannon Janssen, Pierre Blier.   

Abstract

Bupropion is widely used in the treatment of depression. There are, however, limited data on its long-term effects on monoaminergic neurons and therefore the mechanism of its delayed onset of action is at present not well understood. The present study was conducted to examine the effects of prolonged bupropion administration on the firing activity of dorsal raphe nucleus (DRN), locus coeruleus (LC), and ventral tegmental area (VTA) neurons. Spontaneously firing neurons were recorded extracellularly in rats anesthetized with chloral hydrate. Bupropion (30 mg/kg/day) was administered using subcutaneously implanted minipumps. In the DRN, the firing rate of serotonin (5-HT) neurons was significantly increased after 2, 7 and 14 days of administration. The suppressant effect of LSD was significantly diminished after the two-day regimen, indicating a desensitization of 5-HT1A autoreceptors. In the LC, the firing rate of norepinephrine (NE) neurons was significantly attenuated after a 2-day regimen, but recovered progressively over 14 days of administration. The suppressant effect of clonidine on NE neuronal firing was significantly attenuated in rats treated with bupropion for 14 days, indicating a desensitization of alpha2-adrenoceptors. In the VTA, neither 2 nor 14 days of bupropion administration altered the firing and burst activity of dopamine neurons. These results indicate that bupropion, unlike 5-HT reuptake inhibitors, promptly increased 5-HT neuronal activity, due to early desensitization of the 5-HT1A autoreceptor. The gradual recovery of neuronal firing of NE neurons, due to the desensitization of alpha2-adrenoceptors, in the presence of the sustained increase in 5-HT neuronal firing, may explain in part the delayed onset of action of bupropion in major depression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708076     DOI: 10.1016/j.neuropharm.2008.07.028

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  22 in total

1.  Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs.

Authors:  Birgit Abler; Georg Grön; Antonie Hartmann; Coraline Metzger; Martin Walter
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

2.  Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation.

Authors:  Stella Manta; Jianming Dong; Guy Debonnel; Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2009-07       Impact factor: 6.186

3.  Neuroanatomical targets of reboxetine and bupropion as revealed by pharmacological magnetic resonance imaging.

Authors:  Sakthivel Sekar; J Van Audekerke; G Vanhoutte; A S Lowe; A M Blamire; A Van der Linden; T Steckler; M Shoaib; Marleen Verhoye
Journal:  Psychopharmacology (Berl)       Date:  2011-05-07       Impact factor: 4.530

4.  Effects of chronic antidepressant drug administration and electroconvulsive shock on activity of dopaminergic neurons in the ventral tegmentum.

Authors:  Charles H K West; Jay M Weiss
Journal:  Int J Neuropsychopharmacol       Date:  2010-05-19       Impact factor: 5.176

5.  Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion.

Authors:  Ramez Ghanbari; Mostafa El Mansari; Pierre Blier
Journal:  Psychopharmacology (Berl)       Date:  2011-03-29       Impact factor: 4.530

6.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

7.  In Response to Borgsteede et al. About Bupropion and Serotonin Toxicity.

Authors:  Brian Patrick Murray; Joseph Carpenter; Tim P Moran; Diane P Calello; Ziad Kazzi
Journal:  J Med Toxicol       Date:  2020-03-03

8.  Pavlovian drug discrimination with bupropion as a feature positive occasion setter: substitution by methamphetamine and nicotine, but not cocaine.

Authors:  Jamie L Wilkinson; Chia Li; Rick A Bevins
Journal:  Addict Biol       Date:  2008-12-12       Impact factor: 4.280

9.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

10.  Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice.

Authors:  Michel Bourin; Franck Chenu; Corina Prica; Martine Hascoët
Journal:  Psychopharmacology (Berl)       Date:  2009-06-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.